{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:10:52Z","timestamp":1791587452436,"version":"4.3.4"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR202116"],"award-info":[{"award-number":["NIHR202116"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite the broad availability of antihypertensive drugs, approximately 40% of hypertensive patients fail to achieve the recommended blood pressure (BP) levels and may require alternative treatment(s). At present, renal denervation is the only proven non-pharmacological device-based alternative treatment available, but it is a costly, invasive, hospital-based procedure that is unlikely to be widely available. Transcutaneous autonomic neuromodulation (tAN)\u2014if shown to be safe, acceptable, and efficacious\u2014can offer a non-invasive, inexpensive, self-administered device-based innovative adjunct or alternative to pharmacological therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SCRATCH-HTN is a double-blind, sham-controlled trial, with 63 participants randomised on a 2:1 basis to receive either tAN or sham-tAN treatment. Hypertensive patients on medication were included if they had elevated systo-diastolic BPs on daytime ambulatory BP monitoring (ABPM) [systolic BP (SBP) of \u2265135 and &amp;lt;170\u2005mmHg and mean daytime diastolic BP (DBP) of \u226585 and &amp;lt;115\u2005mmHg]. Participants were trained to self-administer tAN therapy for 30\u2005min every day for first 14 days and then once a week for 10 weeks. The primary endpoint was change in daytime ambulatory SBP from baseline to 3 months. Secondary endpoints included change in 24-h ambulatory and office SBP and DBP, BP variability, heart rate variability, quality of life, and sleep quality from baseline to end of treatment. Other exploratory outcomes included evaluation of impact on functional exercise (6-min walk test), structural and functional changes in the heart, cognitive function, and central blood pressures. A subgroup of patients underwent detailed autonomic functional assessment at the start and end of the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The SCRATCH-HTN trial is a phase 2a study testing the safety, acceptability, and potential efficacy of tAN treatment for improving blood pressure control in patients with elevated BP despite medication. It also explores the effects of tAN on sleep, exercise tolerance, heart rate variability, central BP, cardiac structure, and autonomic function. If effective, it could offer a transformative approach to hypertension management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Protocol Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>Clinicaltrials.gov<\/jats:ext-link>\n                      , identifier NCT05179343 and ISRCTN (14509154).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1693086","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:32:57Z","timestamp":1775626377000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["A sham-controlled randomised trial evaluating the safety, acceptability, and efficacy of autonomic neuromodulation using transcutaneous vagal sensory stimulation in uncontrolled hypertensive patients: rationale and study design of the SCRATCH-HTN study"],"prefix":"10.3389","volume":"13","author":[{"given":"Ajay","family":"Gupta","sequence":"first","affiliation":[{"name":"William Harvey Research Institute, Queen Mary University of London","place":["London, United Kingdom"]},{"name":"Barts Heart Centre, St. Bartholomew\u2019s Hospital, Barts Health NHS Trust","place":["London, United Kingdom"]},{"name":"Department of Clinical Pharmacology, The Royal London Hospital, Barts Health NHS Trust","place":["London, United Kingdom"]},{"name":"National Heart & Lung Institute, Imperial College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Collier","sequence":"additional","affiliation":[{"name":"William Harvey Research Institute, Queen Mary University of London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Steckelmacher","sequence":"additional","affiliation":[{"name":"William Harvey Research Institute, Queen Mary University of London","place":["London, United Kingdom"]},{"name":"Barts Heart Centre, St. Bartholomew\u2019s Hospital, Barts Health NHS Trust","place":["London, United Kingdom"]},{"name":"Department of Clinical Pharmacology, The Royal London Hospital, Barts Health NHS Trust","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Field","sequence":"additional","affiliation":[{"name":"William Harvey Research Institute, Queen Mary University of London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Zongo","sequence":"additional","affiliation":[{"name":"William Harvey Research Institute, Queen Mary University of London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mital","family":"Patel","sequence":"additional","affiliation":[{"name":"William Harvey Research Institute, Queen Mary University of London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Collett","sequence":"additional","affiliation":[{"name":"William Harvey Research Institute, Queen Mary University of London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everard","family":"Mascarenhas","sequence":"additional","affiliation":[{"name":"Afferent Medical Solutions Ltd.","place":["Cardiff, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Gourine","sequence":"additional","affiliation":[{"name":"Afferent Medical Solutions Ltd.","place":["Cardiff, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annastazia","family":"Learoyd","sequence":"additional","affiliation":[{"name":"William Harvey Research Institute, Queen Mary University of London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Gourine","sequence":"additional","affiliation":[{"name":"Afferent Medical Solutions Ltd.","place":["Cardiff, United Kingdom"]},{"name":"Centre for Cardiovascular and Metabolic Neuroscience, Neuroscience, Physiology and Pharmacology, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Sever","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"B1","volume-title":"Global Report on Hypertension: The Race Against a Silent Killer","year":"2023"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"20","year":"2021","journal-title":"Lancet Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global Burden of Cardiovascular Diseases and Risks, 1990-2022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B8","volume-title":"Health Survey for England, 2021, Part 2","year":"2023"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e001556","DOI":"10.1136\/bmjmed-2025-001556","article-title":"Trends in hypertension prevalence, control and antihypertensive use in England over the last 2 decades: insights from annual, nationwide Health Surveys for England from 2003 to 2021","volume":"4","author":"Graham","year":"2025","journal-title":"BMJ Med"},{"key":"B10","volume-title":"Tackling High Blood Pressure: From Evidence into Action","year":"2014"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e026582","DOI":"10.1161\/JAHA.122.026582","article-title":"Global burden, regional differences, trends, and health consequences of medication nonadherence for hypertension during 2010 to 2020: a meta-analysis involving 27\u00a0million patients","volume":"11","author":"Lee","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e5641","DOI":"10.1097\/MD.0000000000005641","article-title":"Nonadherence to antihypertensive drugs: a systematic review and meta-analysis","volume":"96","author":"Abegaz","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/ajh\/hpad013","article-title":"Nonadherence is common in patients with apparent resistant hypertension: a systematic review and meta-analysis","volume":"36","author":"Bourque","year":"2023","journal-title":"Am J Hypertens"},{"key":"B14","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.carrev.2019.07.012","article-title":"Renal denervation in the management of hypertension: a meta-analysis of sham-controlled trials","volume":"21","author":"Dahal","year":"2020","journal-title":"Cardiovasc Revasc Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.pcad.2019.12.007","article-title":"Renal denervation: alternative treatment options for hypertension?","volume":"63","author":"Gupta","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"Kandzari","year":"2018","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e034910","DOI":"10.1161\/JAHA.124.034910","article-title":"Randomized trials of renal denervation for uncontrolled hypertension: an updated meta-analysis","volume":"13","author":"Mufarrih","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"568051","DOI":"10.3389\/fnhum.2020.568051","article-title":"International consensus based review and recommendations for minimum reporting standards in research on transcutaneous vagus nerve stimulation (version 2020)","volume":"14","author":"Farmer","year":"2021","journal-title":"Front Hum Neurosci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.brs.2014.07.031","article-title":"Non-invasive vagus nerve stimulation in healthy humans reduces sympathetic nerve activity","volume":"7","author":"Clancy","year":"2014","journal-title":"Brain Stimul"},{"key":"B20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/head.12650","article-title":"Vagus nerve and vagus nerve stimulation, a comprehensive review: part II","volume":"56","author":"Yuan","year":"2016","journal-title":"Headache"},{"key":"B21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/head.12649","article-title":"Vagus nerve and vagus nerve stimulation, a comprehensive review: part III","volume":"56","author":"Yuan","year":"2016","journal-title":"Headache"},{"key":"B22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/head.12647","article-title":"Vagus nerve and vagus nerve stimulation, a comprehensive review: part I","volume":"56","author":"Yuan","year":"2016","journal-title":"Headache"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.18632\/aging.102074","article-title":"Effects of transcutaneous vagus nerve stimulation in individuals aged 55 years or above: potential benefits of daily stimulation","volume":"11","author":"Bretherton","year":"2019","journal-title":"Aging"},{"key":"B24","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.brs.2014.11.018","article-title":"Non-invasive access to the vagus nerve central projections via electrical stimulation of the external ear: fMRI evidence in humans","volume":"8","author":"Frangos","year":"2015","journal-title":"Brain Stimul"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1097\/j.pain.0000000000000930","article-title":"Modulation of brainstem activity and connectivity by respiratory-gated auricular vagal afferent nerve stimulation in migraine patients","volume":"158","author":"Garcia","year":"2017","journal-title":"Pain"},{"key":"B26","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.brs.2013.01.011","article-title":"CNS BOLD fMRI effects of sham-controlled transcutaneous electrical nerve stimulation in the left outer auditory canal\u2014a pilot study","volume":"6","author":"Kraus","year":"2013","journal-title":"Brain Stimul"},{"key":"B27","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.brs.2017.05.006","article-title":"Non-invasive vagus nerve stimulation acutely improves spontaneous cardiac baroreflex sensitivity in healthy young men: a randomized placebo-controlled trial","volume":"10","author":"Antonino","year":"2017","journal-title":"Brain Stimul"},{"key":"B28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.autneu.2016.11.003","article-title":"Effects of short and prolonged transcutaneous vagus nerve stimulation on heart rate variability in healthy subjects","volume":"203","author":"De Couck","year":"2017","journal-title":"Auton Neurosci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s13311-023-01353-9","article-title":"Transcutaneous auricular vagus nerve stimulation (ta-VNS) for treatment of drug-resistant epilepsy: a randomized, double-blind clinical trial","volume":"20","author":"Yang","year":"2023","journal-title":"Neurotherapeutics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.yebeh.2013.02.001","article-title":"Transcutaneous auricular vagus nerve stimulation as a complementary therapy for pediatric epilepsy: a pilot trial","volume":"28","author":"He","year":"2013","journal-title":"Epilepsy Behav"},{"key":"B31","first-page":"551","article-title":"Effects of electrostimulation of the vagus afferent endings in patients with coronary artery disease","volume":"8","author":"Zamotrinsky","year":"1997","journal-title":"Coron Artery Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jacep.2019.11.008","article-title":"TREAT AF (transcutaneous electrical vagus nerve stimulation to suppress atrial fibrillation): a randomized clinical trial","volume":"6","author":"Stavrakis","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jacc.2014.12.026","article-title":"Low-level transcutaneous electrical vagus nerve stimulation suppresses atrial\u00a0fibrillation","volume":"65","author":"Stavrakis","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e032269","DOI":"10.1161\/jaha.123.032269","article-title":"Low-level tragus stimulation attenuates blood pressure in young individuals with hypertension: results from a small-scale single-blind controlled randomized clinical trial","volume":"13","author":"Mbikyo","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e023582","DOI":"10.1161\/jaha.121.023582","article-title":"Neuromodulation of inflammation to treat heart failure with preserved ejection fraction: a pilot randomized clinical trial","volume":"11","author":"Stavrakis","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/B978-0-444-63327-9.00010-2","article-title":"Targeting plasticity with vagus nerve stimulation to treat neurological disease","volume-title":"Changing Brains\u2014Applying Brain Plasticity to Advance and Recover Human Ability","author":"Hays","year":"2013"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e007341","DOI":"10.1161\/jaha.117.007341","article-title":"Bilateral transcutaneous electrical nerve stimulation improves lower-limb motor function in subjects with chronic stroke: a randomized controlled trial","volume":"7","author":"Kwong","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B38","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/sim.4447","article-title":"Preserving the allocation ratio at every allocation with biased coin randomization and minimization in studies with unequal allocation","volume":"31","author":"Kuznetsova","year":"2012","journal-title":"Stat Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1097\/MLR.0b013e318269e121","article-title":"Initial validation of a self-report measure of the extent of and reasons for medication nonadherence","volume":"50","author":"Voils","year":"2012","journal-title":"Med Care"},{"key":"B40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/s1389-9457(00)00065-4","article-title":"Validation of the Insomnia Severity Index as an outcome measure for insomnia research","volume":"2","author":"Bastien","year":"2001","journal-title":"Sleep Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4081\/monaldi.2012.121","article-title":"EuroQol-5D (EQ-5D): an instrument for measuring quality of life","volume":"78","author":"Balestroni","year":"2012","journal-title":"Monaldi Arch Chest Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jneumeth.2013.10.024","article-title":"The psychology experiment building language (PEBL) and PEBL test battery","volume":"222","author":"Mueller","year":"2014","journal-title":"J Neurosci Methods"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.brs.2018.08.010","article-title":"Safety and tolerability of transcutaneous vagus Nerve stimulation in humans; a systematic review","volume":"11","author":"Redgrave","year":"2018","journal-title":"Brain Stimul"},{"key":"B44","doi-asserted-by":"publisher","first-page":"22055","DOI":"10.1038\/s41598-022-25864-1","article-title":"Safety of transcutaneous auricular vagus nerve stimulation (taVNS): a systematic review and meta-analysis","volume":"12","author":"Kim","year":"2022","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/eurheartj\/ehaf037","article-title":"Non-invasive vagus nerve stimulation and exercise capacity in healthy volunteers: a randomized trial","volume":"46","author":"Ackland","year":"2025","journal-title":"Eur Heart J"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","year":"2021","journal-title":"Lancet"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1693086\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:32:58Z","timestamp":1775626378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1693086\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":46,"alternative-id":["10.3389\/fcvm.2026.1693086"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1693086","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"article-number":"1693086"}}